Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura

Haematologica

Volumn 97, Issue 2, 2012, Pages 297-303

  Froehlich Zahnd, Rahel ^a   George, James N ^b,c   Vesely, Sara K ^c   Terrell, Deirdra R ^b,c   Aboulfatova, Khatira ^d   Dong, Jing Fei ^d   Luken, Brenda M ^e,g   Voorberg, Jan ^e   Budde, Ulrich ^f   Sulzer, Irmela ^a   Lämmle, Bernhard ^a   Hovinga, Johanna A Kremer ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e SANQUIN RESEARCH   (Netherlands)

^f Imperial College ^*  (Germany)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

ADAMTS13 activity; ADAMTS13 assays; Anti ADAMTS13 autoantibodies; HIV infection; Thrombotic thrombocy topenic purpura

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL PAIN; ADULT; ANEMIA; ANTIBODY DETECTION; ARTICLE; ATAXIC APHASIA; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CASE REPORT; CHILL; DEATH; DIARRHEA; DRUG WITHDRAWAL; ENZYME ACTIVITY; EPITOPE MAPPING; FEVER; HEMATURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MALE; NAUSEA; OSTEOMYELITIS; PARESTHESIA; PLASMAPHERESIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEINURIA; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIC PURPURA; VOMITING;

ADAM PROTEINS; ADULT; AUTOANTIBODIES; ENZYME ACTIVATION; HUMANS; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE;

EID: 84856427718     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.051433     Document Type: Article

References (29)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589-600.
2. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocy-topenic purpura. Blood. 2008;112(1):11-8.
3. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-11.
4. Lämmle B, Kremer Hovinga JA, George JN. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica. 2008;93 (2):172-7.
5. Benjamin M, Terrell DR, Vesely SK, Voskuhl GW, Dezube BJ, Kremer Hovinga JA, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis. 2009;48(8):1129-37.
6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578-84.
7. Studt JD, Böhm M, Budde U, Girma JP, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multi-center comparison of different assay methods. J Thromb Haemost. 2003;1(9):1882-7.
8. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluoro-genic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
9. Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost. 2006;4(5):1146-8.
10. Zahnd R, Lämmle B, Kremer Hovinga JA. Is the variable clinical presentation in hereditary TTP the result of differences in residual ADAMTS13 activity? Haematologica. 2006;91 (Suppl 1):Abstract 0923.
11. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multi-mers on the endothelial surface under flowing conditions. Blood. 2002;100(12):4033-9.
12. Tripodi A, Chantarangkul V, Böhm M, Budde U, Dong JF, Friedman KD, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost. 2004;2(9):1601-9.
13. Dong J F. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost. 2005;3(8):1710-6.
14. Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, Funato M, et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol. 2001;74(1):101-8.
15. Johnson DA, Gautsch JW, Sportsman JR, Elder JH. Improved technique utilizing nonfat dry milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gene Anal Techn. 1984;1(1):3-8.
16. Kremer Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost. 2007;5(11):2284-90.
17. Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008;6(5):762-71.
18. Studt JD, Budde U, Schneppenheim R, Eisert R, von Depka Prondzinski M, Ganser A, et al. Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry. Am J Clin Pathol. 2001;116(4):567-74.
19. Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpu-ra. Thromb Haemost. 2005;93(2):267-74.
20. Luken BM, Kaijen PH, Turenhout EA, Kremer Hovinga JA, van Mourik JA, Fijnheer R, et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocy-topenic purpura. J Thromb Haemost. 2006;4(11):2355-64.
21. Klaus C, Plaimauer B, Studt JD, Dorner F, Lämmle B, Mannucci PM, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103(12):4514-9.
22. Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epi-tope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood. 2010;115(8):1640-9.
23. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic throm-botic thrombocytopenic purpura. Haematologica. 2010;95(9):1555-62.
24. Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking throm-botic thrombocytopenic purpura. Am J Hematol. 2011;86(9):743-51.
25. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107(2):528-34.
26. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309 (8):453-8.
27. Massabki PS, Accetturi C, Nishie IA, da Silva N P, Sato EI, Andrade LE. Clinical implications of autoantibodies in HIV infection. AIDS. 1997;11(15):1845-50.
28. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 2002; 1(6):329-37.
29. Stratton R, Slapak G, Mahungu T, Kinloch-de Loes S. Autoimmunity and HIV. Curr Opin Infect Dis. 2009;22(1):49-56.